Safer activatable, anti-EGFR bispecific antibodies for metastatic colorectal cancer

用于治疗转移性结直肠癌的更安全的可激活抗 EGFR 双特异性抗体

• 批准号: 710447
• 金额: $ 4.78万
• 依托单位: SHYDEN BIOTECHNOLOGY LTD
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710447
• 关键词: Safer; activatable; anti; EGFR; bispecific

ShyDen Biotechnology is a start-up antibody drug discovery company based in the OpenInnovation incubator, The Stevenage Bioscience Catalyst. It is discovering and developing thenext generation of bispecific antibodies that can be switched on or off, thus carrying a newlevel of molecular regulation and thus safety. This project is to take two clinically-approvedand established monoclonal antibodies and combine them in such a way as to produce abispecific antibody when binding of one arm controls the other. This will be aimed atmetastatic colorectal cancer, but later other solid cancers could be targeted.

ShyDen Biotechnology是一家初创的抗体药物发现公司，位于OpenInnovation孵化器The Stevenage Bioscience Catalyst。它正在发现和开发下一代双特异性抗体，这种抗体可以被打开或关闭，从而携带新的分子调节水平，从而安全。本项目是采用两种临床批准和建立的单克隆抗体，并将它们联合收割机以这样的方式结合，即当一个臂的结合控制另一个臂时，产生非特异性抗体。这将针对转移性结直肠癌，但以后其他实体癌也可以作为目标。